Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141-Reference-Cited by-同舟云学术

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

Published:2022-02-01 Issue:2 Volume:27 Page:e194-e198
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Gillison Maura L¹,Blumenschein George¹,Fayette Jerome²,Guigay Joel³,Colevas A Dimitrios⁴,Licitra Lisa⁵,Harrington Kevin J⁶,Kasper Stefan⁷,Vokes Everett E⁸,Even Caroline⁹,Worden Francis¹⁰,Saba Nabil F¹¹,Iglesias Docampo Lara Carmen¹²,Haddad Robert¹³,Rordorf Tamara¹⁴,Kiyota Naomi¹⁵,Tahara Makoto¹⁶^ORCID,Jayaprakash Vijayvel¹⁷,Wei Li¹⁷,Ferris Robert L¹⁸

Affiliation:

1. Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA

2. Radiation Oncology Department, Centre Leon Berard, Lyon, France

3. Department of Medical Oncology, Centre Antoine Lacassagne, FHU OncoAge, Université Côte d’Azur, Nice, France

4. Department of Medicine - Med/Oncology, Stanford University, Stanford, CA, USA

5. Medical Oncology Head and Neck Cancer Department, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy

6. Division of Radiotherapy and Imaging, Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, National Institute of Health Research Biomedical Research Centre, London, UK

7. Department of Medical Oncology, West German Cancer Center, University Hospital, Essen, Germany

8. Department of Medicine, University of Chicago Medicine and Biological Sciences, Chicago, IL, USA

9. Head and Neck Medical Oncology, Gustave Roussy, Villejuif Cedex, France

10. Department of Medical Oncology, University of Michigan, Ann Arbor, MI, USA

11. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA

12. Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain

13. Division of Head and Neck Oncology, Dana-Farber/Harvard Cancer Center, Boston, MA, USA

14. Clinic for Medical Oncology and Hematology, Universitätsspital Zurich, Zurich, Switzerland

15. Department of Medical Oncology and Hematology, Kobe University Hospital Cancer Center, Kobe, Japan

16. Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan

17. Bristol Myers Squibb, Princeton, NJ, USA

18. Department of Otolaryngology, of Immunology, and of Radiation Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA

Abstract

Abstract In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator’s choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) post-platinum therapy. Nivolumab versus IC as first-line treatment also improved OS among patients with R/M SCCHN who progressed on platinum therapy for locally advanced disease in the adjuvant or primary setting at 1-year follow-up. In the present long-term follow-up analysis of patients receiving first-line treatment, OS benefit with nivolumab (n = 50) versus IC (n = 26) was maintained (median: 7.7 months versus 3.3 months; hazard ratio: 0.56; 95% confidence interval, 0.34-0.94) at 2 years. No new safety signals were identified. In summary, this long-term 2-year analysis of CheckMate 141 supports the use of nivolumab as a first-line treatment for patients with platinum-refractory R/M SCCHN.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://academic.oup.com/oncolo/article-pdf/27/2/e194/42750450/oyab036.pdf

Reference9 articles.

1. Nivolumab for recurrent squamous-cell carcinoma of the head and neck.;Ferris;N Engl J Med.,2016

2. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.;Harrington;Lancet Oncol.,2017

3. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.;Ferris;Oral Oncol.,2018

4. CheckMate 141: 1-year update and subgroup analysis of nivolumab as first-line therapy in patients with recurrent/metastatic head and neck cancer.;Gillison;Oncologist.,2018

5. Evolving role of immunotherapy in recurrent metastatic head and neck cancer.;Le;J Natl Compr Canc Netw.,2020

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives;Immunotherapy;2024-02

2. Radiomic biomarkers for platinum‐refractory head and neck cancer in the era of immunotherapy;Oral Diseases;2024-01-04

3. Cost-benefit analysis of immune checkpoint inhibitors: Is the price worth their value?;Oral Oncology;2023-11

4. Low-dose nivolumab and cabozantinib in recurrent intestinal-type papillary adenocarcinoma of the sinonasal region;BMJ Case Reports;2023-11

5. Review of Outcomes after Salvage Surgery for Recurrent Squamous Cell Carcinoma of the Head and Neck;Cancers;2023-09-23